Our Management
Norman J. Barta - Chairman, President, CEO and Director
Mr. Barta has over 25 years experience in management, finance and systems development. Prior to joining Nephros in 1998, Mr. Barta directed planning and financial management for National Medical Care Research and Development (now a part of the Fresenius organization), the world’s largest dialysis services organization. Earlier experience included cash management and treasury consulting and client management for CoreStates Bank, and large systems development and project management for American Management Systems, Inc.
Mr. Barta received his BS in Mathematics and Economics from Carnegie-Mellon University, with graduate work in economics and operations research, and his MBA from the University of Chicago.
Gerald J. Kochanski - Chief Financial Officer
Mr. Kochanski is a Certified Public Accountant with over thirty years of experience in finance and accounting. With a strong track record in growing companies, he has played a key role in several major corporate collaborations, successfully completing public and private financial transactions. Mr. Kochanski joins the company from Lordi Consulting LLC, where he has served as Director since 2007. Prior to his tenure at Lordi, he spent three years with American Water Enterprises, Inc. as Chief Financial Officer and from 1998 through 2004 was Chief Financial Officer for Scanvec Amiable Limited. Prior to 1991, Mr. Kochanski demonstrated his financial and management leadership at Gist-Brocades Food Ingredients, Inc., Keystone Franklin, Inc. and Airshields, Inc. Mr. Kochanski started his career in public accounting at Price Waterhouse & Co.
Mr. Kochanski earned his Bachelor's degree and MBA from LaSalle University.
Joleen C. Turner - VP of Marketing and Business Development
Ms. Turner has over twenty years of international experience in strategic marketing, product development and product commercialization with high technology, professional service and life-science corporations. Since June 2006, she has been an independent consultant working with companies such as Boehringer Ingelheim, Pfizer, and Pepsico. She recently led a major marketing and packaging launch of a leading respiratory combination drug with revenues now exceeding US $1 billion. Previously Ms. Turner held the position of Director, Strategic Programs, for Aris Global where her strategic marketing initiatives contributed to the company's record growth and success in the safety, regulatory and medical information markets. Prior to her tenure at Aris Global, Ms. Turner served in various senior management positions at Platinum Technologies, Arthur D. Little Inc, and Recognition Equipment. Ms. Turner started her career as a software development engineer at Raytheon Data Systems.
Ms. Turner received a B.S. degree in Health Sciences from California State University, holds an MBA and Ph.D. degree in Business Administration and is a candidate for an M.S. degree in marketing from Alfred Whitehead College, Redlands University.
Gregory Collins, Ph.D. - Senior Scientist
R&D Program Manager with National Medical Care. BS in Chemical Engineering, Arizona State University; Ph.D. in Bioengineering, UC San Diego.
Nephros International
Dara Gannon - Customer Service Manager
12 years experience in customer service and sales environment. Sales management position with Ireland’s leading hotel group. Marketing Coordinator for Chicago-based investment group. MA International Relations, Dublin City University, B.A. French & Sociology, Trinity College Dublin.
Our Board of Directors
Eric A. Rose, M.D. has served as our lead director since August 2006, and as chairman of our Board of Directors from 1997 until 2006 and a director since our inception in 1997. Dr. Rose served as our president and chief executive officer from May 1999 until July 2002. Dr. Rose has been Executive Vice President Life Sciences of MacAndrews & Forbes Holdings Inc. since March 2007 and Chairman & Chief Executive Officer of SIGA Technologies, Inc. (“SIGA”), a publicly-traded biotechnology company focused on the design and development of novel products for the prevention and treatment of serious infectious diseases, since March 2007. Since 1994, Dr. Rose has been the Morris and Rose Millstein/Johnson & Johnson Professor and Chairman of the Department of Surgery at the Columbia University College of Physicians and Surgeons, and Surgeon in Chief at the Columbia Presbyterian Medical Center. Beginning March 2007, Dr. Rose is on leave from this position. Dr. Rose is a director of the following corporations which are required to file reports pursuant to the Exchange Act of 1934, as amended (the “Exchange Act”): SIGA and Keryx Biopharmaceuticals, Inc. Dr. Rose is also a director of PharmaCore, Inc., TransTech Pharma, Inc. and a former director of Nexell Therapeutics Inc. (f/k/a VimRx). Dr. Rose received a B.A., summa cum laude, in Psychology from Columbia University and an M.D. from Columbia University College of Physicians and Surgeons.
Arthur H. Amron has served as a director of our company since September 2007. Mr. Amron is a partner of Wexford Capital and serves as its General Counsel. Mr. Amron also actively participates in various private equity transactions, particularly in the bankruptcy and restructuring areas, and has served on the boards and creditors’ committees of a number of public and private companies in which Wexford has held investments. From 1991-94, Mr. Amron was an Associate at Schulte Roth & Zabel LLP specializing in corporate and bankruptcy law and from 1984-91, Mr. Amron was an Associate at Debevoise & Plimpton LLP specializing in corporate litigation and bankruptcy law. Mr. Amron holds a JD from Harvard University, a BA in political theory from Colgate University and is a member of the New York Bar.
Lawrence J. Centella has served as a director of our company since January 2001. Mr. Centella serves as president of Renal Patient Services, LLC, a company that owns and operates dialysis centers, and has served in such capacity since June 1998. From 1997 to 1998, Mr. Centella served as executive vice president and chief operating officer of Gambro Healthcare, Inc., an integrated dialysis company that manufactured dialysis equipment, supplied dialysis equipment and operated dialysis clinics. From 1993 to 1997, Mr. Centella served as president and chief executive officer of Gambro Healthcare Patient Services, Inc. (formerly REN Corporation). Prior to that, Mr. Centella served as president of COBE Renal Care, Inc., Gambro Hospal, Inc., LADA International, Inc. and Gambro, Inc. Mr. Centella is also the founder of LADA International, Inc. Mr. Centella received a B.S. from DePaul University.
Paul A. Mieyal has served as a director of our company since September 2007. Dr. Mieyal has been a Vice President of Wexford Capital since October 2006. From January 2006 through September 2006, he was Vice President in charge of healthcare investments for Wechsler & Co., Inc., a private investment firm and registered broker-dealer. Dr. Mieyal is also a director of Nile Therapeutics, Inc. Dr. Mieyal received his Ph.D. in pharmacology from New York Medical College, a B.A. in chemistry and psychology from Case Western Reserve University, and is a Chartered Financial Analyst.
James S. Scibetta has served as a director of our company since November 2007. Prior to joining us, Mr. Scibetta was Chief Financial Officer of Bioenvision, Inc. from December 2006 until its acquisition by Genzyme, Inc. in October 2007. From September 2001 to November 2006, Mr. Scibetta was Executive Vice President and CFO of Merrimack Pharmaceuticals, Inc., a biopharmaceutical company focused on discovery and development of novel therapies for autoimmune disease and cancer, and he was a member of the Board of Directors of Merrimack from April 1998 to March 2004. Mr. Scibetta formerly served as a senior investment banker at Shattuck Hammond Partners, LLC from 1997 to 2001 and PaineWebber Inc. from 1988 to 1997, providing capital acquisition, mergers and acquisitions, and strategic advisory services to healthcare companies. Mr. Scibetta is currently a member of the Board of Directors and Audit Committee Chairman of Labopharm, Inc., an international specialty pharmaceutical company focused on improving existing drugs by incorporating its proprietary, advanced controlled-release technologies. Mr. Scibetta holds a B.S. in Physics from Wake Forest University, and an M.B.A. in Finance from the University of Michigan. He completed executive education studies in the Harvard Business School Leadership & Strategy in Pharmaceuticals and Biotechnology program.
Scientific Advisory Board
John T. Daugirdas, MD - University of Illinois at Chicago School of Medicine Associate. Chief of Staff for research and Development, VA Chicago - Westside Medical Center. Co-author The Handbook of Dialysis.
Detlef Krieter, MD - Fellow at the University of Goettingen and University of Wuerzburg, Germany, and University of Montpellier and Renal Research and Training Institute, Montpellier, France; consultant at the Nephrology Center of Lower Saxony, Germany. Active researcher in the field of extracorporeal renal replacement therapies.
Leonard Stern, MD FACP - Medical Director at Columbia University Dialysis Center, and Assistant Professor of Clinical Medicine, Columbia University, College of Physician and Surgeons.
|
